Company Filing History:
Years Active: 2021-2023
Title: Pernilla Sandwall: Innovator in Inflammatory Bowel Disease Treatment
Introduction
Pernilla Sandwall is a notable inventor based in Stockholm, Sweden. She has made significant contributions to the field of medical research, particularly in the treatment of inflammatory bowel disease. With a total of 2 patents to her name, her work is paving the way for innovative therapeutic solutions.
Latest Patents
Pernilla's latest patents include a groundbreaking oligonucleotide designed for the treatment of inflammatory bowel disease. The first patent provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2) for use in treating this condition in human subjects. Individual doses ranging from 100 mg to 350 mg are administered on at least four separate occasions, with each occasion spaced a week apart. The second patent focuses on Cobitolimod, which also utilizes the same oligonucleotide sequence for treatment. In this case, doses of 150 mg to 350 mg are given on at least two separate occasions, with the occasions spaced three weeks apart.
Career Highlights
Pernilla Sandwall is currently associated with Index Pharmaceuticals AB, where she continues her research and development efforts. Her work is crucial in advancing therapeutic options for patients suffering from inflammatory bowel disease.
Collaborations
Pernilla collaborates with talented individuals in her field, including Arezou Zargari and Charlotte Admyre. Their combined expertise contributes to the innovative research being conducted at Index Pharmaceuticals AB.
Conclusion
Pernilla Sandwall's contributions to the treatment of inflammatory bowel disease through her patents highlight her role as a significant innovator in the medical field. Her ongoing work promises to enhance therapeutic strategies for patients in need.